Matt Calistri | Vice President of Corporate Strategy and Investor Relations |
Anthony Coles | Chairperson and Chief Executive Officer |
Raymond Sanchez | Chief Medical Officer |
John Renger | Chief Scientific Officer |
Mark Bodenrader | Interim Chief Financial Officer |
Abraham Ceesay | President |
Umer Raffat | Evercore |
Michael Yee | Jefferies |
Paul Matteis | Stifel |
Tazeen Ahmad | Bank of America |
Max Skor | Morgan Stanley |
Mohit Bansal | Wells Fargo |
Rob Palermo | Goldman Sachs |
Charles Duncan | Cantor Fitzgerad |
Douglas Tsao | H.C. Wainwright |
Good morning, and welcome to the Cerevel Therapeutics Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the Q&A portion of the call. Please note that this call may be recorded. I will now hand the call over to Matt Calistri, Vice President of Investor Relations.